Montelukast is used to prevent and treat asthma symptoms and to relieve nasal congestion from allergies. It works by blocking substances in the body that cause inflammation and narrowing of airways.[1] Singulair is currently being investigated across 3 indications[3], with its most advanced program in Preclinical.[1]
Singulair is one of 57 small molecule programs targeting Rhinitis, Allergic, Perennial. It is currently in Preclinical.
Indications
Total Trials
Active Trials
Competitors
Pipeline
Competition
317 competitors in COVID-19
Nitrostat
Low-Molecular-Weight Heparin
Glucocorticoid
Statins
Rayaldee
SARS-COV-2 VACCINE
Biological Data
Blood Collection
Biological Collection
Singulair
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Sources
Details